The impact of a multi-species probiotic supplementation on clinical symptoms and biochemical factors in patients with irritable bowel syndrome: a randomised controlled trial.

IF 2.7 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Archives of Physiology and Biochemistry Pub Date : 2025-05-20 DOI:10.1080/13813455.2025.2507749

Shirin Hajiani, Maryam Tajabadi Ebrahimi, Amir Sadeghi, Nakisa Zarrabi Ahrabi, Abbas Yadegar

{"title":"The impact of a multi-species probiotic supplementation on clinical symptoms and biochemical factors in patients with irritable bowel syndrome: a randomised controlled trial.","authors":"Shirin Hajiani, Maryam Tajabadi Ebrahimi, Amir Sadeghi, Nakisa Zarrabi Ahrabi, Abbas Yadegar","doi":"10.1080/13813455.2025.2507749","DOIUrl":null,"url":null,"abstract":"Background: Intestinal inflammation and oxidative stress contribute to the pathophysiology of irritable bowel syndrome (IBS). This clinical trial investigated the effects of a probiotic supplementation on symptom severity and quality of life (QOL) in IBS patients.Methods: Forty-six IBS patients were randomised to receive either a multi-species probiotic or placebo for 8 weeks. Clinical symptoms were evaluated using the IBS Severity Scoring System (IBS-SSS) and IBS QOL questionnaire. Serum levels of IFN-γ, IL-1β, IL-10, IL-6, malondialdehyde (MDA), total antioxidant capacity (TAC), and nitric oxide (NO) were measured before and after the intervention.Results: After 8 weeks, the probiotic group showed significant improvements in QOL scores, and reductions in IBS-SSS and MDA levels compared to placebo group. TAC levels were significantly higher in probiotic group. However, no significant differences were observed in cytokine or NO levels.Conclusions: This multi-species probiotic supplement was safe and effective in reducing symptom severity and improved QOL of IBS patients.","PeriodicalId":8331,"journal":{"name":"Archives of Physiology and Biochemistry","volume":" ","pages":"1-11"},"PeriodicalIF":2.7000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Physiology and Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13813455.2025.2507749","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Intestinal inflammation and oxidative stress contribute to the pathophysiology of irritable bowel syndrome (IBS). This clinical trial investigated the effects of a probiotic supplementation on symptom severity and quality of life (QOL) in IBS patients.

Methods: Forty-six IBS patients were randomised to receive either a multi-species probiotic or placebo for 8 weeks. Clinical symptoms were evaluated using the IBS Severity Scoring System (IBS-SSS) and IBS QOL questionnaire. Serum levels of IFN-γ, IL-1β, IL-10, IL-6, malondialdehyde (MDA), total antioxidant capacity (TAC), and nitric oxide (NO) were measured before and after the intervention.

Results: After 8 weeks, the probiotic group showed significant improvements in QOL scores, and reductions in IBS-SSS and MDA levels compared to placebo group. TAC levels were significantly higher in probiotic group. However, no significant differences were observed in cytokine or NO levels.

Conclusions: This multi-species probiotic supplement was safe and effective in reducing symptom severity and improved QOL of IBS patients.

查看原文本刊更多论文

多品种益生菌补充对肠易激综合征患者临床症状和生化因素的影响：一项随机对照试验

背景：肠道炎症和氧化应激参与肠易激综合征（IBS）的病理生理。本临床试验研究了益生菌补充剂对IBS患者症状严重程度和生活质量（QOL）的影响。方法：46例肠易激综合征患者随机接受8周的多品种益生菌或安慰剂治疗。采用IBS严重程度评分系统（IBS- sss）和IBS生活质量问卷对临床症状进行评估。检测干预前后血清IFN-γ、IL-1β、IL-10、IL-6、丙二醛（MDA）、总抗氧化能力（TAC）、一氧化氮（NO）水平。结果：8周后，与安慰剂组相比，益生菌组的生活质量评分显著改善，IBS-SSS和MDA水平降低。益生菌组TAC水平显著高于对照组。然而，细胞因子和no水平无显著差异。结论：该多菌种益生菌制剂可安全有效地减轻IBS患者的症状严重程度，改善患者的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archives of Physiology and Biochemistry ENDOCRINOLOGY & METABOLISM-PHYSIOLOGY

CiteScore

6.90

自引率

3.30%

发文量

期刊介绍： Archives of Physiology and Biochemistry: The Journal of Metabolic Diseases is an international peer-reviewed journal which has been relaunched to meet the increasing demand for integrated publication on molecular, biochemical and cellular aspects of metabolic diseases, as well as clinical and therapeutic strategies for their treatment. It publishes full-length original articles, rapid papers, reviews and mini-reviews on selected topics. It is the overall goal of the journal to disseminate novel approaches to an improved understanding of major metabolic disorders. The scope encompasses all topics related to the molecular and cellular pathophysiology of metabolic diseases like obesity, type 2 diabetes and the metabolic syndrome, and their associated complications. Clinical studies are considered as an integral part of the Journal and should be related to one of the following topics: -Dysregulation of hormone receptors and signal transduction -Contribution of gene variants and gene regulatory processes -Impairment of intermediary metabolism at the cellular level -Secretion and metabolism of peptides and other factors that mediate cellular crosstalk -Therapeutic strategies for managing metabolic diseases Special issues dedicated to topics in the field will be published regularly.